Lexaria Bioscience (LEXX) Change in Inventory (2014 - 2023)
Lexaria Bioscience (LEXX) posted Change in Inventory of -$76782.0 for Q2 2023, down 219.03% sequentially from $64504.0 in Q1 2023, and down 641.35% YoY from $14183.3 in Q2 2022.
Lexaria Bioscience (LEXX) Change in Inventory (2014 - 2023) Analysis & Trends
Lexaria Bioscience has reported Change in Inventory for 10 years, with the latest figure at -$76782.0 in Q2 2023.
- Quarterly Change in Inventory fell 641.35% year-over-year to -$76782.0 in Q2 2023, while the trailing twelve-month figure through Feb 2024 was -$76782.0 (down 351.14% YoY) and the FY2023 annual result came in at -$43069.0, down 2076.3% from the prior year.
- Change in Inventory eased to -$76782.0 in Q2 2023 per LEXX's latest filing, from $64504.0 in the prior quarter.
- Over five years, Change in Inventory peaked at $80257.0 in Q2 2019 and troughed at -$88859.0 in Q2 2021.
- A 5-year average of -$6553.4 and a median of -$5782.0 in 2019 frame the typical range for Change in Inventory.
- The sharpest annual moves came in 2022 and 2023: Change in Inventory tumbled 956.66% in 2022, then soared 1482.92% in 2023.
- Over 5 years, Change in Inventory stood at $6160.0 in 2019, then declined by 1.51% to $6067.0 in 2020, then slumped by 148.03% to -$2914.0 in 2021, then sank by 956.66% to -$30791.0 in 2022, then tumbled by 149.37% to -$76782.0 in 2023.
- According to Business Quant data, Change in Inventory over the past three periods registered -$76782.0, $64504.0, and -$30791.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 132.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 47.15 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -280,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 135.26 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 12.97 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2023 | -76,782.00 |
| May 31, 2023 | -76,782.00 |
| Feb 28, 2023 | 64,504.00 |
| Feb 28, 2023 | 64,504.00 |
| Nov 30, 2022 | -30,791.00 |
| Nov 30, 2022 | -30,791.00 |
| Aug 31, 2022 | 7,217.00 |
| Aug 31, 2022 | 7,217.00 |
| May 31, 2022 | -10,357.00 |
| May 31, 2022 | -10,357.00 |
| Feb 28, 2022 | 4,075.00 |
| Feb 28, 2022 | 4,075.00 |
| Nov 30, 2021 | -2,914.00 |
| Nov 30, 2021 | -2,914.00 |
| Aug 31, 2021 | -23,061.00 |
| Aug 31, 2021 | -23,061.00 |
| May 31, 2021 | -88,859.00 |
| May 31, 2021 | -88,859.00 |
| Feb 28, 2021 | 10,816.00 |
| Feb 28, 2021 | 10,816.00 |